Caladrius Biosciences Inc (CLBS.OQ)
CLBS.OQ on NASDAQ Stock Exchange Capital Market
1.75USD
2 Jul 2020
1.75USD
2 Jul 2020
Change (% chg)
$-0.02 (-1.13%)
$-0.02 (-1.13%)
Prev Close
$1.77
$1.77
Open
$1.78
$1.78
Day's High
$1.82
$1.82
Day's Low
$1.75
$1.75
Volume
31,113
31,113
Avg. Vol
58,579
58,579
52-wk High
$3.58
$3.58
52-wk Low
$1.15
$1.15
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.41 | December | 4 Jul 2020 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 0 | 0 | 0 | 0 |
| (2) OUTPERFORM | 3 | 3 | 2 | 2 |
| (3) HOLD | 1 | 1 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.25 | 2.25 | 2.00 | 2.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-20 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 4 | 0.00 | 0.00 | 0.00 | 5.00 |
| Year Ending Dec-21 | 4 | 5.18 | 15.00 | 0.00 | 15.00 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | 4 | -0.41 | -0.33 | -0.48 | -0.43 |
| Quarter Ending Dec-20 | 4 | -0.40 | -0.34 | -0.44 | -0.43 |
| Year Ending Dec-20 | 4 | -1.56 | -1.36 | -1.70 | -1.31 |
| Year Ending Dec-21 | 4 | -0.93 | -0.53 | -1.79 | -0.70 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Jun-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-20 | -0.29 | -0.38 | 0.09 | -31.03 |
| Quarter Ending Dec-19 | -0.34 | -0.47 | 0.12 | -36.23 |
| Quarter Ending Sep-19 | -0.43 | -0.47 | 0.04 | -9.30 |
| Quarter Ending Jun-19 | -0.44 | -0.49 | 0.05 | -10.11 |
| Quarter Ending Mar-19 | -0.43 | -0.44 | 0.01 | -3.53 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00 |
| Year Ending Dec-21 | 5.18 | 5.18 | 5.18 | 11.46 | 15.00 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | -0.41 | -0.41 | -0.41 | -0.31 | -0.43 |
| Quarter Ending Dec-20 | -0.40 | -0.40 | -0.40 | -0.31 | -0.43 |
| Year Ending Dec-20 | -1.56 | -1.56 | -1.56 | -1.20 | -1.31 |
| Year Ending Dec-21 | -0.93 | -0.93 | -0.93 | -0.44 | -0.70 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-20 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-21 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Sep-20 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-21 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Caladrius Biosciences Files Prospectus Relates To Resale Of Up To 2.1 Mln Common Shares By Selling Stockholders - SEC Filing
- BRIEF-Caladrius Biosciences To Present On CLBS119 For COVID-19 Induced Lung Damage
- BRIEF-Caladrius Biosciences Announces Presentation Of Full Results For CLBS16 From The Escape-CMD Trial At SCAI 2020 Scientific Sessions
- BRIEF-Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- BRIEF-Caladrius Biosciences Reports Fourth Quarter And Full Year 2019 Financial Results